New Realm Media is pleased to announce that Medicinal Organic Cannabis Australia (MOCA), a federally licensed medical cannabis company, has commissioned a clinical study to explore the usage patterns and motivations of CBD users and its role in the health supplement industry. The study is international in scope and has been initiated under the leadership of Dr. Eliane Karsaklian, a senior professor at the Sorbonne (University of Paris) and visiting professor at the University of Chicago.
CBD, or Cannabidiol, is a cannabinoid found in the cannabis plant that has gained significant attention in recent years for its health benefits. It is recognised as the second most prevalent active ingredient of cannabis (marijuana) and has shown substantial evidence that it could be a powerful anti-anxiety therapy. CBD is commonly used to treat childhood epilepsy syndromes, such as Dravet syndrome and Lennox-Gastaut syndrome (LGS), anxiety, insomnia, and chronic pain.
According to MOCA's CEO, Alessandro Sorbello, "The research is much needed to better understand how CBD fits into the medical framework. In the United States, CBD is sold over the counter and is widely available; you can find it in a myriad of products from beverages to gummy bears. This Australian led scientific research involves academics based in Europe, the United States, Australia, and Asia and will encompass tens of thousands of CBD users."
The World Health Organisation has reported that in humans, CBD exhibits no effects indicative of any abuse or dependence potential. To date, there is no evidence of public health-related problems associated with the use of pure CBD.
MOCA's clinical study is a significant step forward in understanding the benefits of CBD and its role in the medical and health supplement industry.